PharmTech's monthly newsletter, Equipment and Processing Report, reviews the Editor's Picks for the September 2012 edition from Uhlmann Packaging Systems and GE Healthcare.
Uhlmann Packaging Systems
Integrated blister and carton module features simplified changeover
Uhlmann Packaging Systems’ Blister Express Center 500 (BEC 500) is a double-lane, integrated blister and carton module that can process up to 500 blisters and 500 cartons per minute, which makes it ideal for packaging medium-sized batches of standard, solid-dose products. The flexible machine is available with rotary or platen sealing and can produce complex shapes, rigid aluminum pockets, calendar packs, and other nontraditional packages. Between runs, the machine features a newly simplified changeover process that allows a single person to completely reset the entire line in just 30 minutes without the use of tools. Uhlmann’s new SmartControl operating system offers step-by-step guidance through the entire format changeover.
GE Healthcare
Modular, prefabricated bioprocessing facility reduces construction time and capital investment compared to traditional facilities
GE Healthcare’s KUBio modular, 1200-m2 bioprocessing facility is prefabricated and delivered with a complete, ready-to-use production line that is based on GE Healthcare’s Ready-to-Process single-use technologies. The total planning, delivery, and construction time of the facility is 14–18 months, which is significantly less than the 24–36 months needed for traditional construction. Capital investment is also significantly reduced.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.